Conventional wisdom holds that COVID-19 is a respiratory disease — a virus that colonizes the lungs and, for most patients, stays there. The epidemiological picture emerging several years into the pandemic complicates that view considerably. A substantial and expanding body of population-level research now links SARS-CoV-2 infection to elevated cardiovascular risk: heart attack, stroke, and related vascular events. Persisting well beyond the acute phase of illness. The mechanism, as it turns out, begins not in the lungs but at a single cell-surface receptor.
View our featured gallery: COVID-19 and Cardiovascular Disease →
It Starts With a Receptor, Not the Lungs
The link between SARS-CoV-2 and cardiovascular pathology begins with angiotensin-converting enzyme 2 (ACE2), a protein expressed on the surface of cells throughout the body, where it normally helps regulate blood pressure. ACE2 also happens to be the virus's entry point: the spike protein binds to it with notable specificity, in essentially a lock-and-key fashion.
The lungs draw the most clinical attention because alveolar cells are especially rich in ACE2 and tend to be where infection first becomes symptomatic. But ACE2 is expressed just as prominently on the endothelial cells lining blood vessels throughout the circulatory system — which is precisely what reframes this from a purely respiratory illness into a systemic vascular one.
Artery fully blocked, atherosclerosis, scanning electron micrograph. © NYPL / Science Source
A small etymological aside, for anyone who appreciates one: "corona" is Latin for crown, a reference to the ring of spike proteins studding the viral envelope, which under electron microscopy genuinely does resemble a coronet. A fitting name, given how much of the pathology traces back to that structure.
What Happens to Blood Vessels During Infection
Blood vessels are lined by a single layer of cells, the endothelium, which is, remarkably, thinner than a sheet of paper yet performs an outsized physiological role: keeping blood flowing smoothly, regulating clotting, and controlling what passes into surrounding tissue.
When SARS-CoV-2 infects or provokes inflammation in endothelial cells, the resulting condition, endothelial dysfunction, alters vessel behavior in several consequential ways:
Increased endothelial "stickiness," raising the likelihood of platelets and clotting factors adhering to vessel walls
A broader systemic inflammatory response, which further irritates vascular tissue
Disruption of the normal balance between clot formation and clot breakdown
None of this occurs in isolation. It's the underlying reason COVID-19 has been associated with elevated rates of clotting events — not only during acute infection, but for months afterward.
Who's Most at Risk?
Transient ischemic attack (TIA). © Sue Seif / Science Source
Cardiovascular risk following COVID-19 isn't uniformly distributed across a population. Several well-established factors appear to compound it, and readers with any familiarity with cardiovascular health will recognize most of them immediately:
Age: older adults carry elevated risk both during acute infection and in its aftermath.
Obesity: independently associated with more severe COVID-19 illness and, separately, with cardiovascular risk generally.
Diabetes: a known contributor to vascular damage on its own, which appears to compound COVID-related vascular stress rather than merely coexist with it.
Hypertension: among the most frequently observed comorbidities in COVID patients who go on to experience cardiac or cerebrovascular events.
Pre-existing cardiovascular disease: a prior heart attack, stroke, or diagnosed cardiac condition raises baseline risk considerably.
Smoking: a well-documented contributor to endothelial damage that appears to layer onto, rather than operate independently of, COVID-related vascular effects.
None of these risk factors are unique to COVID-19; they're the same variables that appear in cardiovascular health conversations more broadly. What's notable is how consistently they recur across COVID-cardiovascular research specifically — suggesting the virus may be amplifying existing vulnerabilities rather than introducing an entirely new risk pathway.
Stroke, Heart Attack, and the Long Tail of "Long COVID"
The cardiovascular effects of COVID-19 show up in more than one form, and across more than one timeline.
Myocardial infarction: partial destruction of the heart muscle, due stenosis, angiography. © James Cavallini / Science Source
Ischemic stroke — the result of a blood clot obstructing blood flow to the brain — is the subtype most consistently associated with COVID-19, consistent with the virus's broader tendency to promote clotting. Stroke medicine has a well-known saying, "time is brain," reflecting how quickly neural tissue is affected once blood flow is interrupted — part of why any stroke symptoms warrant immediate emergency evaluation.
Cardiac involvement extends well beyond stroke:
Heart attack (myocardial infarction): resulting from blocked coronary blood flow, via the same clotting mechanism implicated in ischemic stroke.
Myocarditis: inflammation of the heart muscle, reported at elevated rates following SARS-CoV-2 infection.
Arrhythmia: irregular heartbeat, another effect linked to post-COVID inflammatory processes.
Deep vein thrombosis and pulmonary embolism: clotting conditions affecting the legs and lungs, respectively, both consistent with COVID-19's broader effect on clotting.
Timing is a meaningful variable here. Some events occur during or shortly after acute infection, while hospitalized patients are already under close monitoring. Others manifest considerably later, often discussed under the "long COVID" umbrella, underscoring that cardiovascular risk isn't confined to the acute or most severe phase of illness.
A Story Best Told With the Right Imagery
None of this is visible to the unaided eye: a spike protein engaging a receptor, an inflamed vessel wall, a clot forming inside an artery. That's where strong imagery does what prose can't.
Our collection covers this topic in full: micrographs of clots and damaged endothelium, precise illustrations of stroke and heart attack, and diagnostic imaging of real clinical presentations, all backed by accurate metadata. With more than sixty years sourcing and vetting science and medical imagery, we're also glad to help track down exactly what a piece needs — free of charge, as part of the research support we offer every client.